Patient Education for LDL-C–Lowering Therapies

EP: 1.Unmet Needs in the Management of Patients with Hyperlipidemia

EP: 2.Target LDL-C Levels for Patients

EP: 3.Guideline Recommendations for LDL-C Management

EP: 4.Weighing the Benefits and Risks of Statin Therapy

EP: 5.Important Treatment Considerations With LDL-C– Lowering Therapies

EP: 6.Effective Approaches for Utilizing Nonstatin Therapies

EP: 7.Mechanisms of Action of Nonstatin Therapies

EP: 8.Cost and Safety of Novel, Nonstatin Therapies

EP: 9.Clinical Value of Nonstatin Therapies

EP: 10.Deciding Between Novel, Nonstatin Therapies

EP: 11.Optimizing Treatment of Patients on LDL-C–Lowering Therapies

EP: 12.Identifying Nonadherence in Patients With Hyperlipidemia

Now Viewing

EP: 13.Patient Education for LDL-C–Lowering Therapies

EP: 14.Monitoring Patients for Adverse Events and Optimizing Access to Therapies

EP: 15.Additional Considerations for LDL-C–Lowering Therapies

EP: 16.Future Considerations for the Management of Hyperlipidemia

Optimizing LDL-C Management: A Summary for Physicians

Patient Education Key Points

• Emphasize LDL-C level as a primary modifiable risk factor for cardiovascular disease and the relationship between lower LDL-C levels and improved outcomes
• Explain the incremental cardiovascular benefit of progressive LDL-C reduction below traditional target levels
• Present treatment options in a risk-benefit framework that includes proven mortality/morbidity benefits vs potential adverse effects
• Address common misconceptions about statin therapy and other lipid-lowering medications
• Use visual aids and simplified risk calculators to improve patient understanding of their personal cardiovascular risk
• Discuss lifestyle modifications as foundational therapy that enhances medication effectiveness

Treatment Selection Strategies

• Implement a stepwise approach starting with high-intensity statins as first-line therapy
• Consider nonstatin therapies (e.g., ezetimibe, PCSK9 inhibitors, and bempedoic acid) based on:
  • Residual risk after maximum-tolerated statin therapy
  • Baseline risk profile (prioritizing highest-risk patients for combination therapy)
  • Prior medication tolerance and response
  • Cost-effectiveness and insurance coverage constraints
• Personalize treatment intensity based on individual risk factors, comorbidities, and LDL-C reduction target levels
• Establish clear thresholds for therapy intensification based on risk stratification
• Develop institution-specific protocols that incorporate cost considerations and local formulary constraints
• Consider patient preferences and medication adherence factors in therapy selection